What’s Going On With Oncorus (ONCR) Stock Friday?

Oncorus, Inc. (NASDAQ: ONCR) shares are soaring Friday on abnormally high volume. The stock appears to be seeing increased attention ahead of the company's impending liquidation. What's Going On:

Oncorus, Inc. (NASDAQ:ONCR) shares are soaring Friday on abnormally high volume. The stock appears to be seeing increased attention ahead of the company’s impending liquidation.

What’s Going On:

  • Last Friday, the company’s board announced it approved a liquidation and ONCR shares are set to be suspended from the Nasdaq on June 20. 
  • On June 1, 2023, Oncorus announced its workforce reduction plan, which stated that the company is assessing all strategic options to maximize value for stakeholders, including an acquisition, merger, reverse merger, licensing, divesture of assets or other transactions

Oncorus has an average session volume of just over 1.3 million, according to Benzinga Pro. Friday’s trading volume has already exceeded 139 million at publication time. The stock is also seeing increased message volume on Stocktwits and brokerage chat rooms as traders circle the name. 

Related News: What’s Going On With Adobe Stock Friday
ONCR Price Action: Despite Friday’s surge, ONCR shares are still down nearly 30% over the last month and more than 80% over the last year. ONCR shares were up 17- % at 21 cents at the time of publication, according to Benzinga Pro.

Image: Gerd Altmann from Pixabay

Total
0
Shares
Related Posts
Read More

Reported Late Tuesday March 7, FDA Accepts Mesoblast’s Resubmission Of The Biologic License Application For Remestemcel-L In Children With Steroid-Refractory Acute Graft Versus Host Disease As A Complete Response And Sets Goal Date Of August 2, 2023

Mesoblast Limited (NASDAQ:MESO, ASX:MSB)))), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration's (FDA) Office of Therapeutic

MESO